Isothermal Diagnostics Instrument Articles & Analysis
11 news found
Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors. ...
Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. ...
The funding will be used to develop a rapid diagnostic that will identify immune subtypes (“endotypes”) of sepsis to enable better therapy selection and resource allocation. ...
Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021. ...
Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. ...
Inflammatix a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. ...
Inflammatix a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads the immune system to predict severe respiratory failure risk in COVID-19 patients. ...
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced the publication of a health economic model that shows use of the company’s HostDxTM Sepsis test in patients suspected of acute respiratory tract infections (ARTI) in Emergency Departments is cost-effective versus standard-of-care. ...
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced the appointment of João Fonseca, Ph.D., as Chief Technology Officer. ...
“To wit, 100% of the patients in this cohort were on antibiotics, but many did not have an underlying bacterial infection. Improved diagnostics would benefit patients and have a major impact on the healthcare system,” said Dr. ...
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced a $32 million Series C financing. ...